Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M

Aktis Oncology, Inc.

FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.
AKY-1189 (Nectin-4) granted Fast Track designation for urothelial cancer in Feb 2026; Phase 1b enrolling.
Pro forma cash of $562.1M (incl. $335.3M net from Jan 2026 IPO) expected to fund operations into 2029.
FY2025 net loss $63.7M vs $44.0M; R&D spend $67.5M (+65% YoY) driven by clinical advancement.
Collaboration revenue from Eli Lilly partnership totaled $6.5M in FY2025, up from $1.5M in FY2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aktis Oncology, Inc. reported the year ended December 31, 2025 results: revenue $6.5 million.

Period: the year ended December 31, 2025
Revenue: $6.5 million
Result: reported results

Exact text from the filing

the January 2026 IPO. The Company believes that the pro forma as adjusted cash position will fund its operations into 2029. • Collaboration revenue: Collaboration revenue was $6.5 million for the year ended December 31, 2025, compared to $1.5 million for the year ended December 31, 2024. The increase was attributable to revenue recognized under the Company’s

View on SEC.gov

1350 earnings releases filed in the last 30 days. Browse all earnings releases →

Aktis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-132524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.